modelAdenosine_1
Extends from Pharmacolibrary.Drugs.ATC.C.C01EB10_1.
Information
| name: | Adenosine_1 | |
| ATC code: | C01EB10_1 | route: | oral |
| compartments: | 1 | |
| dosage: | 10 | mg |
| volume of distribution: | 0.21 | L |
| clearance: | 15 | L/min |
| other parameters in model implementation | ||
Adenosine is an endogenous purine nucleoside approved for the rapid conversion of paroxysmal supraventricular tachycardia (PSVT) to normal sinus rhythm. It acts on adenosine receptors to inhibit conduction through the atrioventricular node and is used primarily in acute cardiac care settings. Adenosine is approved and widely used today as an intravenous antiarrhythmic agent.
Pharmacokinetics
Estimated pharmacokinetic parameters for oral administration; not clinically relevant due to very low oral bioavailability.
References
Tayama, T, et al., & Kagawa, Y (2024). Population Pharmacokinetics of the Novel Adenosine A. Clinical pharmacology in drug development 13(5) 549–559. DOI:10.1002/cpdd.1359 PUBMED:https://pubmed.ncbi.nlm.nih.gov/38178727
Liu, S, et al., & Tian, X (2018). Population pharmacokinetics and pharmacodynamics of ticagrelor and AR-C124910XX in Chinese healthy male subjects. European journal of clinical pharmacology 74(6) 745–754. DOI:10.1007/s00228-018-2427-3 PUBMED:https://pubmed.ncbi.nlm.nih.gov/29442148
Röshammar, D, et al., & Hamrén, B (2017). Population pharmacokinetics of ticagrelor and AR-C124910XX in patients with prior myocardial infarction . International journal of clinical pharmacology and therapeutics 55(5) 416–424. DOI:10.5414/CP202748 PUBMED:https://pubmed.ncbi.nlm.nih.gov/28139972
Parameters
| Type | Name | Default | Description |
|---|---|---|---|
| Modelica.Units.SI.Mass | weight (from PK_1C) | 75 | patient weight (kg) |
| Modelica.Units.SI.SpecificVolume | VdPerKg (from PK_1C) | 0.9 | Volume of distribution (L/kg) |
| Modelica.Units.SI.MassFraction | F (from PK_1C) | 0.8 | bioavailiability (0-1) |
| Pharmacolibrary.Types.Clearance | Cl (from PK_1C) | 20 | clearance |
| Modelica.Units.SI.Time | adminTime (from PK_1C) | 60 | first administration time (s) |
| Modelica.Units.SI.Time | adminDuration (from PK_1C) | 600 | administration duration (s) |
| Modelica.Units.SI.Time | adminPeriod (from PK_1C) | 8*60*60 | period of administration (default 8 hours)(s) |
| Pharmacolibrary.Types.Mass | adminMass (from PK_1C) | 1000 | administration mass (mg) |
| Integer | adminCount (from PK_1C) | 8 | number of dose administered (1) |
| Pharmacolibrary.Types.Volume | Vd (from PK_1C) | VdPerKg*weight | Volume of distribution (m3) |
| Pharmacolibrary.Types.MassConcentration | Cmin (from PK_1C) | 0.004 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Cmax (from PK_1C) | 0.008 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Ctox_peak (from PK_1C) | 0.012 | toxicity peak level |
| Pharmacolibrary.Types.MassConcentration | Ctox_trough (from PK_1C) | 0.006 | toxicity trough level |
| Pharmacolibrary.Types.TransferRate | ka (from PK_1C_enteral) | 0.016666666666666666 | first order absorption rate |
| Modelica.Units.SI.Time | Tlag (from PK_1C_enteral) | 600 | delay between oral administration and absorption (default 10min) |
Connectors
| Type | Name | Default | Description |
|---|---|---|---|
| Types.ConcentrationOutput | C_central (from PK_1C) | ||
| Interfaces.ConcentrationPort_b | centralCPort (from PK_1C) |
Components
| Type | Name | Default | Description |
|---|---|---|---|
| Pharmacokinetic.NoPerfusedTissueCompartment | central (from PK_1C) | ||
| Pharmacokinetic.ClearanceDrivenElimination | elim (from PK_1C) | ||
| Sources.PeriodicDose | periodicDose (from PK_1C) | ||
| Modelica.Units.SI.Time | t1_2 (from PK_1C) | elimination half-life |
Revisions
- 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)